Payment overview · 2025
General Payments
$526.66
26 reported records · 12 companies
Healthcare provider profile · identity verified
Kenneth E. Rose, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MUSCLE SHOALS, AL · NPI 1215921978
Verified facts
What the public records show
CMS Open Payments records show Kenneth E. Rose, M.D. received $526.66 in general payments during 2025 across 26 reported records.
Merck Sharp & Dohme LLC accounted for 22.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $118.35 | 22.5% | 5 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $78.77 | 15.0% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.62 | 14.0% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $48.52 | 9.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.17 | 8.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.46 | 8.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.88 | 6.2% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.28 | 4.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.67 | 3.7% | 1 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $17.83 | 3.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.78 | 2.8% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.33 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $526.66 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $78.77 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.96 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.96 | 3 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $53.96 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $51.54 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $48.52 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $30.12 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $29.44 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.79 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.79 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.67 | 1 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 202 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 109 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 202 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
253 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
202 | 47 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
109 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
202 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1873 | 357 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1334 | 256 |
| Omeprazole | Omeprazole | 1242 | 211 |
| Amlodipine Besylate | Amlodipine Besylate | 1195 | 249 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1111 | 185 |
| Metoprolol Succinate | Metoprolol Succinate | 948 | 217 |
| Potassium Chloride | Potassium Chloride | 861 | 124 |
| Losartan Potassium | Losartan Potassium | 761 | 201 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 761 | 188 |
| Metformin Hcl | Metformin Hcl | 750 | 145 |
| Furosemide | Furosemide | 731 | 133 |
| Lisinopril | Lisinopril | 718 | 198 |
| Eliquis | Apixaban | 687 | 73 |
| Gabapentin | Gabapentin | 663 | 174 |
| Meloxicam | Meloxicam | 611 | 135 |
| Tamsulosin Hcl | Tamsulosin Hcl | 566 | 104 |
| Citalopram Hbr | Citalopram Hydrobromide | 463 | 87 |
| Spironolactone | Spironolactone | 462 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 460 | 51 |
| Trazodone Hcl | Trazodone Hcl | 447 | 101 |
| Donepezil Hcl | Donepezil Hcl | 434 | 68 |
| Carvedilol | Carvedilol | 417 | 54 |
| Famotidine | Famotidine | 407 | 79 |
| Pravastatin Sodium | Pravastatin Sodium | 389 | 60 |
| Montelukast Sodium | Montelukast Sodium | 363 | 87 |
| Tramadol Hcl | Tramadol Hcl | 353 | 90 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 341 | 81 |
| Simvastatin | Simvastatin | 341 | 101 |
| Metoprolol Tartrate | Metoprolol Tartrate | 339 | 64 |
| Duloxetine Hcl | Duloxetine Hcl | 338 | 55 |
| Hydralazine Hcl | Hydralazine Hcl | 328 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 328 | 30 |
| Sertraline Hcl | Sertraline Hcl | 327 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 326 | 51 |
| Metformin Hcl Er | Metformin Hcl | 311 | 86 |
| Divalproex Sodium | Divalproex Sodium | 302 | 15 |
| Allopurinol | Allopurinol | 299 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 293 | 109 |
| Buspirone Hcl | Buspirone Hcl | 266 | 23 |
| Farxiga | Dapagliflozin Propanediol | 253 | 31 |
| Propranolol Hcl | Propranolol Hcl | 253 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 249 | 72 |
| Clonazepam | Clonazepam | 247 | 54 |
| Levetiracetam | Levetiracetam | 239 | 13 |
| Xarelto | Rivaroxaban | 214 | 22 |
| Jardiance | Empagliflozin | 202 | 47 |
| Ozempic | Semaglutide | 202 | 46 |
| Alendronate Sodium | Alendronate Sodium | 200 | 47 |
| Ezetimibe | Ezetimibe | 192 | 43 |
| Methocarbamol | Methocarbamol | 191 | 48 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 189 | 79 |
| Oxcarbazepine | Oxcarbazepine | 187 | suppressed |
| Memantine Hcl | Memantine Hcl | 182 | 31 |
| Paroxetine Hcl | Paroxetine Hcl | 182 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 180 | 54 |
| Glimepiride | Glimepiride | 177 | 53 |
| Ropinirole Hcl | Ropinirole Hcl | 171 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 163 | 38 |
| Baclofen | Baclofen | 160 | 15 |
| Bupropion Xl | Bupropion Hcl | 151 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 151 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 145 | 35 |
| Mirtazapine | Mirtazapine | 143 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 139 | 20 |
| Irbesartan | Irbesartan | 139 | 28 |
| Sucralfate | Sucralfate | 130 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 125 | 36 |
| Januvia | Sitagliptin Phosphate | 122 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 122 | 36 |
| Alprazolam | Alprazolam | 120 | 38 |
| Amitriptyline Hcl | Amitriptyline Hcl | 117 | 27 |
| Pregabalin | Pregabalin | 117 | 29 |
| Risperidone | Risperidone | 114 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 113 | suppressed |
| Glipizide | Glipizide | 113 | 15 |
| Valsartan | Valsartan | 110 | 30 |
| Mounjaro | Tirzepatide | 109 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 107 | 31 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 101 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 101 | 19 |
| Finasteride | Finasteride | 100 | 35 |
| Tradjenta | Linagliptin | 100 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 94 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 93 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 21 |
| Temazepam | Temazepam | 89 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 73 |
| Clonidine Hcl | Clonidine Hcl | 86 | 28 |
| Labetalol Hcl | Labetalol Hcl | 86 | suppressed |
| Torsemide | Torsemide | 84 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 83 | 34 |
| Atenolol | Atenolol | 82 | 27 |
| Gemtesa | Vibegron | 81 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 80 | suppressed |
| Estradiol | Estradiol | 78 | 20 |
| Ranolazine Er | Ranolazine | 77 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 76 | suppressed |
| Olanzapine | Olanzapine | 76 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 76 | 12 |
| Prednisone | Prednisone | 76 | 34 |
| Morphine Sulfate Er | Morphine Sulfate | 74 | suppressed |
| Azithromycin | Azithromycin | 72 | 67 |
| Benazepril Hcl | Benazepril Hcl | 72 | suppressed |
| Cefdinir | Cefdinir | 72 | 63 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 72 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 71 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 71 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 18 |
| Divalproex Sodium Er | Divalproex Sodium | 69 | suppressed |
| Ibuprofen | Ibuprofen | 69 | 29 |
| Lansoprazole | Lansoprazole | 67 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 66 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 21 |
| Ziprasidone Hcl | Ziprasidone Hcl | 64 | suppressed |
| Lovastatin | Lovastatin | 62 | suppressed |
| Primidone | Primidone | 61 | suppressed |
| Lorazepam | Lorazepam | 60 | 23 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 59 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 57 | suppressed |
| Celecoxib | Celecoxib | 57 | 24 |
| Vascepa | Icosapent Ethyl | 57 | suppressed |
| Repatha Sureclick | Evolocumab | 55 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 19 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | 12 |
| Synthroid | Levothyroxine Sodium | 52 | 23 |
| Topiramate | Topiramate | 52 | suppressed |
| Ondansetron Odt | Ondansetron | 51 | 34 |
| Gemfibrozil | Gemfibrozil | 50 | 18 |
| Flecainide Acetate | Flecainide Acetate | 49 | suppressed |
| Digoxin | Digoxin | 48 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 47 | suppressed |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Carbamazepine Er | Carbamazepine | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Lamotrigine | Lamotrigine | 45 | suppressed |
| Calcium Acetate | Calcium Acetate | 44 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 43 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 36 |
| Fluconazole | Fluconazole | 42 | 32 |
| Nabumetone | Nabumetone | 40 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 38 | suppressed |
| Cephalexin | Cephalexin | 37 | 36 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 37 | suppressed |
| Methimazole | Methimazole | 36 | suppressed |
| Phenytoin | Phenytoin | 36 | suppressed |
| Valproic Acid | Valproic Acid | 36 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 35 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 35 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 35 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate | 34 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | 12 |
| Diazepam | Diazepam | 32 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 14 |
| Trulicity | Dulaglutide | 30 | 11 |
| Chlorthalidone | Chlorthalidone | 29 | 13 |
| Nitroglycerin | Nitroglycerin | 29 | 18 |
| Enulose | Lactulose | 27 | suppressed |
| Linzess | Linaclotide | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 26 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 25 | 24 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 25 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | 12 |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Xifaxan | Rifaximin | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Clonidine | Clonidine | 16 | suppressed |
| Nystatin | Nystatin | 16 | 14 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Klor-Con M10 | Potassium Chloride | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Fluocinonide-E | Fluocinonide/Emollient Base | 13 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Humulin R | Insulin Regular, Human | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $526.66 · 26 records | Merck Sharp & Dohme LLC | Auvelity, BREZTRI, CABENUVA, CAPVAXIVE, Dexcom G6 Transmitter, EVENITY, Fluad, Flucelvax, JARDIANCE, Kimyrsa, MOUNJARO, Ozempic, PIFELTRO, PROLIA, Rezzayo, Rybelsus, VOWST, Wegovy, ZEPBOUND, ZERBAXA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error